KalVista Pharmaceuticals Long Term Debt

KalVista Pharmaceuticals (KALV) currently reports a long-term debt of $270M as of January 2026. That compares with $4.3M in the prior-year period — up 6101.4% year over year. Use the charts on this page to explore KalVista Pharmaceuticals's long-term debt history and peer comparisons.

KalVista Pharmaceuticals's long-term debt increased from $4.3M to $270M — a 6101.4% year-over-year increase (period ending January 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

KalVista Pharmaceuticals reported $270M in long-term debt as of January 2026. That compares with $4.3M in the prior-year period — up 6101.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $270M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for KalVista Pharmaceuticals, and consider following KALV for alerts when major investors trade the stock.

KalVista Pharmaceuticals is classified in the Healthcare sector. On long-term debt, it currently shows $270M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing KALV with unrelated industries.